Cyllene Therapeutics announced the closing of a €33 million Series C financing round. The company was formerly known as EG 427 and rebranded to Cyllene Therapeutics alongside the financing. The round was co-led by GordonMD Global Investments and Merck Ventures, an affiliate of Merck KGaA, Darmstadt, Germany. T. Andera Partners, Bpifrance Investissement through its InnoBio 3 Fund, and Lamond Ventures also participated.
The funding will support the clinical development of EG110A, Cyllene’s lead DNA medicine candidate for severe neurogenic bladder conditions. The proceeds will also help expand the company’s proprietary HERMES non-replicating HSV-1 platform.
Cyllene said its new name honors the mythical birthplace of Hermes and the platform that defines the company. Its HERMES platform is designed to deliver targeted neurotherapeutics for diseases of the peripheral and central nervous system.
EG110A is being developed for multiple severe bladder diseases. In ongoing studies, the candidate has demonstrated substantial and sustained reductions in urinary incontinence episodes for at least nine months after treatment in patients with spinal cord injury-related neurogenic detrusor overactivity.
Cyllene plans to begin a Phase 2b/3 study in 2027. The company also intends to expand development into overactive bladder and additional neurological indications.
GordonMD selected Cyllene as a portfolio cornerstone based on EG110A’s early clinical signal and the versatility of the HERMES platform. The firm focuses on identifying transformative biopharma therapies with the potential to redefine standards of care.
Cyllene Therapeutics is focused on non-replicating HSV-1 vector technology in neurology. The company said its platform could improve patient outcomes and reduce healthcare costs across severe neurological and bladder diseases.
KEY QUOTES:
“The preliminary clinical results of EG110A support the application of precision therapeutics within neuro-urology. With this funding, Cyllene is positioned for global expansion into major neurological indications including pain and migraine.”
Craig Gordon, MD, Founder, CEO and CIO of GordonMD
“This financing marks a defining moment as we advance EG110A toward later-stage development and broaden our HERMES pipeline. Early data support our belief that localized DNA medicines can deliver durable efficacy with a strong safety profile in chronic neurological diseases.”
Philippe Chambon, MD, PhD, CEO of Cyllene
